292 related articles for article (PubMed ID: 25730262)
1. 10-iodo-11H-indolo[3,2-c]quinoline-6-carboxylic acids are selective inhibitors of DYRK1A.
Falke H; Chaikuad A; Becker A; Loaëc N; Lozach O; Abu Jhaisha S; Becker W; Jones PG; Preu L; Baumann K; Knapp S; Meijer L; Kunick C
J Med Chem; 2015 Apr; 58(7):3131-43. PubMed ID: 25730262
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and optimization of an original V-shaped collection of 4-7-disubstituted pyrido[3,2-d]pyrimidines as CDK5 and DYRK1A inhibitors.
Dehbi O; Tikad A; Bourg S; Bonnet P; Lozach O; Meijer L; Aadil M; Akssira M; Guillaumet G; Routier S
Eur J Med Chem; 2014 Jun; 80():352-63. PubMed ID: 24793883
[TBL] [Abstract][Full Text] [Related]
3. Exploiting the repertoire of CK2 inhibitors to target DYRK and PIM kinases.
Cozza G; Sarno S; Ruzzene M; Girardi C; Orzeszko A; Kazimierczuk Z; Zagotto G; Bonaiuto E; Di Paolo ML; Pinna LA
Biochim Biophys Acta; 2013 Jul; 1834(7):1402-9. PubMed ID: 23360763
[TBL] [Abstract][Full Text] [Related]
4. Computational & experimental evaluation of the structure/activity relationship of β-carbolines as DYRK1A inhibitors.
Drung B; Scholz C; Barbosa VA; Nazari A; Sarragiotto MH; Schmidt B
Bioorg Med Chem Lett; 2014 Oct; 24(20):4854-60. PubMed ID: 25240617
[TBL] [Abstract][Full Text] [Related]
5. Pharmacophore and 3D-QSAR characterization of 6-arylquinazolin-4-amines as Cdc2-like kinase 4 (Clk4) and dual specificity tyrosine-phosphorylation-regulated kinase 1A (Dyrk1A) inhibitors.
Pan Y; Wang Y; Bryant SH
J Chem Inf Model; 2013 Apr; 53(4):938-47. PubMed ID: 23496085
[TBL] [Abstract][Full Text] [Related]
6. Selective inhibition of the kinase DYRK1A by targeting its folding process.
Kii I; Sumida Y; Goto T; Sonamoto R; Okuno Y; Yoshida S; Kato-Sumida T; Koike Y; Abe M; Nonaka Y; Ikura T; Ito N; Shibuya H; Hosoya T; Hagiwara M
Nat Commun; 2016 Apr; 7():11391. PubMed ID: 27102360
[TBL] [Abstract][Full Text] [Related]
7. Insights into mechanism of pyrido[2,3-d]pyrimidines as DYRK1A inhibitors based on molecular dynamic simulations.
Li JJ; Tian YL; Zhai HL; Lv M; Zhang XY
Proteins; 2016 Aug; 84(8):1108-23. PubMed ID: 27119584
[TBL] [Abstract][Full Text] [Related]
8. Meridianin derivatives as potent Dyrk1A inhibitors and neuroprotective agents.
Yadav RR; Sharma S; Joshi P; Wani A; Vishwakarma RA; Kumar A; Bharate SB
Bioorg Med Chem Lett; 2015 Aug; 25(15):2948-52. PubMed ID: 26048785
[TBL] [Abstract][Full Text] [Related]
9. DYRK1A kinase inhibitors with emphasis on cancer.
Ionescu A; Dufrasne F; Gelbcke M; Jabin I; Kiss R; Lamoral-Theys D
Mini Rev Med Chem; 2012 Nov; 12(13):1315-29. PubMed ID: 23016545
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of new pyridazino[4,5-b]indol-4-ones and pyridazin-3(2H)-one analogs as DYRK1A inhibitors.
Bruel A; Bénéteau R; Chabanne M; Lozach O; Le Guevel R; Ravache M; Bénédetti H; Meijer L; Logé C; Robert JM
Bioorg Med Chem Lett; 2014 Nov; 24(21):5037-40. PubMed ID: 25248682
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of a library of lead-like 2,4-bisheterocyclic substituted thiophenes as selective Dyrk/Clk inhibitors.
Schmitt C; Kail D; Mariano M; Empting M; Weber N; Paul T; Hartmann RW; Engel M
PLoS One; 2014; 9(3):e87851. PubMed ID: 24676346
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of substituted 6-arylquinazolin-4-amines as potent and selective inhibitors of cdc2-like kinases (Clk).
Mott BT; Tanega C; Shen M; Maloney DJ; Shinn P; Leister W; Marugan JJ; Inglese J; Austin CP; Misteli T; Auld DS; Thomas CJ
Bioorg Med Chem Lett; 2009 Dec; 19(23):6700-5. PubMed ID: 19837585
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of dual specificity kinase activity of DYRK1A.
Walte A; Rüben K; Birner-Gruenberger R; Preisinger C; Bamberg-Lemper S; Hilz N; Bracher F; Becker W
FEBS J; 2013 Sep; 280(18):4495-511. PubMed ID: 23809146
[TBL] [Abstract][Full Text] [Related]
14. Harmine is an ATP-competitive inhibitor for dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A).
Adayev T; Wegiel J; Hwang YW
Arch Biochem Biophys; 2011 Mar; 507(2):212-8. PubMed ID: 21185805
[TBL] [Abstract][Full Text] [Related]
15. Activation, regulation, and inhibition of DYRK1A.
Becker W; Sippl W
FEBS J; 2011 Jan; 278(2):246-56. PubMed ID: 21126318
[TBL] [Abstract][Full Text] [Related]
16. QSAR analysis of pyrazolidine-3,5-diones derivatives as Dyrk1A inhibitors.
Koo KA; Kim ND; Chon YS; Jung MS; Lee BJ; Kim JH; Song WJ
Bioorg Med Chem Lett; 2009 Apr; 19(8):2324-8. PubMed ID: 19282176
[TBL] [Abstract][Full Text] [Related]
17. Pyrido[2,3-d]pyrimidines: discovery and preliminary SAR of a novel series of DYRK1B and DYRK1A inhibitors.
Anderson K; Chen Y; Chen Z; Dominique R; Glenn K; He Y; Janson C; Luk KC; Lukacs C; Polonskaia A; Qiao Q; Railkar A; Rossman P; Sun H; Xiang Q; Vilenchik M; Wovkulich P; Zhang X
Bioorg Med Chem Lett; 2013 Dec; 23(24):6610-5. PubMed ID: 24239188
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of thiazolo[5,4-f]quinazolines as DYRK1A inhibitors, part II.
Foucourt A; Hédou D; Dubouilh-Benard C; Girard A; Taverne T; Casagrande AS; Désiré L; Leblond B; Besson T
Molecules; 2014 Sep; 19(10):15411-39. PubMed ID: 25264830
[TBL] [Abstract][Full Text] [Related]
19. Development of novel molecular probes of the Rio1 atypical protein kinase.
Mielecki M; Krawiec K; Kiburu I; Grzelak K; Zagórski W; Kierdaszuk B; Kowa K; Fokt I; Szymanski S; Swierk P; Szeja W; Priebe W; Lesyng B; LaRonde-LeBlanc N
Biochim Biophys Acta; 2013 Jul; 1834(7):1292-301. PubMed ID: 23523885
[TBL] [Abstract][Full Text] [Related]
20. Identification of a DYRK1A Inhibitor that Induces Degradation of the Target Kinase using Co-chaperone CDC37 fused with Luciferase nanoKAZ.
Sonamoto R; Kii I; Koike Y; Sumida Y; Kato-Sumida T; Okuno Y; Hosoya T; Hagiwara M
Sci Rep; 2015 Aug; 5():12728. PubMed ID: 26234946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
